HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

LEADS BIOLABS-B

59.000

-0.500-0.84%

Volume:447.70K

Turnover:26.45M

Market Cap:11.74B

PE:-29.38

High:60.900

Open:59.000

Low:57.200

Close:59.500

52wk High:83.600

52wk Low:51.600

Shares:199.00M

HK Float Shares:153.00M

Volume Ratio:1.31

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.008

ROE:--

ROA:--

PB:102.26

PE(LYR):-29.38

PS:- -

Loading ...

Overview Company News Filings

Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase II Trial for First-Line Hepatocellular Carcinoma

Bulletin Express

LEADS BIOLABS-B (09887): First Patient Dosed in Phase II Trial of LBL-024 as First-Line Treatment for Hepatocellular Carcinoma

Nanjing Leads Biolabs Doses First Patient in Phase II Trial of LBL-024 for Liver Cancer

HK Stock Announcement Highlights | SOFTCARE to List Tomorrow; FIH Expects Significant Improvement in Annual Financial Performance

Nanjing Leads Biolabs (9887) Announces Inclusion in MSCI Global Small Cap Indexes

Bulletin Express

LEADS BIOLABS-B (09887) Included in MSCI Global Small Cap Index

Nanjing Leads Biolabs Co. Ltd. to Join MSCI Global Small Cap Indexes

Nanjing Leads Biolabs - Inclusion in MSCI Global Small Cap Indexes Effective Nov 24, 2025

THOMSON REUTERS

HK Stock Movement | LEADS BIOLABS-B (09887) Rises Over 3% as Five Hematology Research Findings Presented at 2025 ASH Annual Meeting

Nanjing Leads Biolabs (09887) Releases Monthly Securities Movements for October 2025

Bulletin Express

LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting

Nanjing Leads Biolabs Announces Positive Phase I/II Results for LBL-034 in Relapsed Multiple Myeloma

Nanjing Leads Biolabs Doses First Patient in Biliary Tract Cancer Drug Trial

MT Newswires Live

Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase II Trial for Biliary Tract Cancer

Bulletin Express

LEADS BIOLABS-B (09887): First Patient Dosed in Phase II Trial of LBL-024 for First-Line Biliary Tract Cancer Treatment

Nanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement

Bulletin Express

Nanjing Leads Biolabs Updates Details of Exclusive Global License Agreement with Additional Payment Information

BRIEF-Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus

LEADS BIOLABS-B (09887) Signs Global Exclusive License Agreement with DIANTHUS for LBL-047

Nanjing Leads Biolabs - Exclusive Global License Agreement With Dianthus for Lbl-047

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/09887/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":59,"timestamp":1763102203051,"preClose":59.5,"halted":0,"volume":447700,"delay":0,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"Trading","change":-0.5,"latestTime":"11-14 14:37:06","open":59,"high":60.9,"low":57.2,"amount":26448585,"amplitude":0.062185,"askPrice":59.15,"askSize":1100,"bidPrice":59,"bidSize":1800,"shortable":3,"etf":0,"ttmEps":-1.858667,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1763107800000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":59.5,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.314209,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":1.314209,"shares":199000000,"dividePrice":0,"high":60.9,"amplitude":0.062185,"preClose":59.5,"low":57.2,"week52Low":51.6,"pbRate":"102.26","week52High":83.6,"institutionHeld":0,"latestPrice":59,"committee":0.241379,"eps":-2.008042,"divideRate":0,"volume":447700,"delay":0,"ttmEps":-1.858667,"open":59,"prevYearClose":35,"prevWeekClose":58.45,"prevMonthClose":53.7,"prevQuarterClose":69.95,"fiveDayClose":58.45,"twentyDayClose":66.25,"sixtyDayClose":73.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-11-12","current":-32.012189,"percent":0.933333,"low":-50.052922,"twenty":-44.115151,"median":-41.529709,"eighty":-39.201212,"high":-34.030535,"avg":-41.427746,"sd":3.156628,"marketCap":11416389320},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-12","current":-36.397343,"twenty":-44.115151,"median":-41.529709,"eighty":-39.201212,"marketCap":11416389320}],"updateTime":1763059415624},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1101918459","title":"Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase II Trial for First-Line Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1101918459","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101918459?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:54","pubTimestamp":1762764870,"startTime":"0","endTime":"0","summary":"Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited do not accept responsibility for the contents of the original announcement, make no representation as to its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1179684957","title":"LEADS BIOLABS-B (09887): First Patient Dosed in Phase II Trial of LBL-024 as First-Line Treatment for Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1179684957","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179684957?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:46","pubTimestamp":1762764384,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase II clinical study evaluating oplitelimab (PD-L1/4-1BB bispecific antibody LBL-024) as a first-line...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2582825908","title":"Nanjing Leads Biolabs Doses First Patient in Phase II Trial of LBL-024 for Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825908","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582825908?lang=en_us&edition=fundamental","pubTime":"2025-11-10 16:41","pubTimestamp":1762764115,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. has announced the initiation of a Phase II clinical trial for Opamtistomig , a PD-L1/4-1BB bispecific antibody, as a first-line treatment for hepatocellular carcinoma. The first patient has been successfully dosed in this open-label, multi-center study, which is led by Professor Jian Zhou of Zhongshan Hospital, Fudan University, and is being conducted across multiple hospitals in China. The company previously received approval from the National Medical Products Administration for a single-arm registrational trial in April 2024, as well as Breakthrough Therapy Designation for LBL-024 in late-line advanced EP-NEC and Orphan Drug Designation from the U.S. FDA for neuroendocrine carcinoma. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL8z7m1q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1199117456","title":"HK Stock Announcement Highlights | SOFTCARE to List Tomorrow; FIH Expects Significant Improvement in Annual Financial Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=1199117456","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199117456?lang=en_us&edition=fundamental","pubTime":"2025-11-09 20:04","pubTimestamp":1762689852,"startTime":"0","endTime":"0","summary":"**Key Updates**   - **SOFTCARE (02698)**: Hong Kong public offering oversubscribed by 1,813.77 times, expected to list on November 10.   - **HENGRUI PHARMA (01276)**: HRS-2430 and SHR-4610 injections...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU0359201885.HKD","02038","BK1160","00434","LU1023057109.AUD","BK1526","LU0359201612.USD","BK1161","02698","BK1612","09887","BK1191","BK1508","BK1504","01276","BK1531","BK1104","BK1167","LU0359202008.SGD"],"gpt_icon":1},{"id":"1120305355","title":"Nanjing Leads Biolabs (9887) Announces Inclusion in MSCI Global Small Cap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=1120305355","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120305355?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:22","pubTimestamp":1762489365,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that its shares will be included in the MSCI Global Small Cap Indexes effective after the market close on November 24, 2025. This...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1120952844","title":"LEADS BIOLABS-B (09887) Included in MSCI Global Small Cap Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1120952844","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120952844?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:08","pubTimestamp":1762488492,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the company will be added to the MSCI Global Small Cap Index, effective after the market close on November 24, 2025. The MSCI Global Small Cap Index, compiled...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSCI","LU2210150020.SGD","LU2210149790.SGD","LU0175139822.USD","LU2095319765.USD","BK4112","LU0289960550.SGD","LU0289961442.SGD","LU0672654240.SGD","LU1804176565.USD","IE00BKPKM429.USD","LU1691799644.USD","BK4585","LU0109391861.USD","09887","LU0390134368.USD","LU0708995401.HKD","LU2265009873.SGD","LU0320765059.SGD","BK1161","LU0511384066.AUD","LU1267930730.SGD","BK4588","LU0289739343.SGD"],"gpt_icon":0},{"id":"2581024902","title":"Nanjing Leads Biolabs Co. Ltd. to Join MSCI Global Small Cap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2581024902","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581024902?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:07","pubTimestamp":1762488429,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. will be added to the MSCI Global Small Cap Indexes after the market close on 24 November 2025. The company's inclusion reflects recognition from global investors of its operating performance and development potential.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL4D7VM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2581246620","title":"Nanjing Leads Biolabs - Inclusion in MSCI Global Small Cap Indexes Effective Nov 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581246620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581246620?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:01","pubTimestamp":1762488064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WI33S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1116382406","title":"HK Stock Movement | LEADS BIOLABS-B (09887) Rises Over 3% as Five Hematology Research Findings Presented at 2025 ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1116382406","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116382406?lang=en_us&edition=fundamental","pubTime":"2025-11-05 11:28","pubTimestamp":1762313292,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) surged more than 3%, reaching HK$57.9 by the time of writing, with a trading volume of HK$20.2056 million. On November 4, the company announced that five research abstracts...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LU2463526074.USD","09887","BK1161","ASH"],"gpt_icon":0},{"id":"1167289834","title":"Nanjing Leads Biolabs (09887) Releases Monthly Securities Movements for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1167289834","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167289834?lang=en_us&edition=fundamental","pubTime":"2025-11-04 16:46","pubTimestamp":1762245974,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (stock code: 09887) published its monthly return details for the period ended 31 October 2025. According to the announcement, the total authorised and registered share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1101815562","title":"LEADS BIOLABS-B (09887): LBL-034 Clinical Study Selected as First Oral Presentation on Opening Day of 67th ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1101815562","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101815562?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:40","pubTimestamp":1762209616,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH). The company is pleased to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","LU2463526074.USD","ASH","09887","BK1161"],"gpt_icon":0},{"id":"2580306229","title":"Nanjing Leads Biolabs Announces Positive Phase I/II Results for LBL-034 in Relapsed Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2580306229","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580306229?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:10","pubTimestamp":1762207812,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL43pDlZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2578646013","title":"Nanjing Leads Biolabs Doses First Patient in Biliary Tract Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2578646013","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578646013?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:35","pubTimestamp":1761568530,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (HKG:9887) dosed the first patient in a phase II clinical study evaluating Opamtistomig for the treatment of biliary tract cancer, a Monday Hong Kong bourse filing said.The trial aims to evaluate the efficacy and safety of the drug in combination regimens.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1105009514","title":"Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase II Trial for Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1105009514","media":"Bulletin Express","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105009514?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:19","pubTimestamp":1761563960,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) announced that the first patient has been dosed in a Phase II clinical study evaluating Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"1175359537","title":"LEADS BIOLABS-B (09887): First Patient Dosed in Phase II Trial of LBL-024 for First-Line Biliary Tract Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1175359537","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175359537?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:14","pubTimestamp":1761560055,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase II clinical trial evaluating oplitelimab (PD-L1/4-1BB bispecific antibody LBL-024) as a first-line...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"1185591939","title":"Nanjing Leads Biolabs (9887) Issues Clarification on License Agreement Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1185591939","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185591939?lang=en_us&edition=fundamental","pubTime":"2025-10-17 17:31","pubTimestamp":1760693480,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) released a clarification regarding its Exclusive Global License Agreement announcements dated October 16, 2025. According to the company, the second...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2576804930","title":"Nanjing Leads Biolabs Updates Details of Exclusive Global License Agreement with Additional Payment Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2576804930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576804930?lang=en_us&edition=fundamental","pubTime":"2025-10-17 17:19","pubTimestamp":1760692763,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. issued a clarification announcement regarding its recent entry into an Exclusive Global License Agreement. The company updated its previous announcement to include additional details about the payment structure associated with the agreement. The revised announcement specifies that the agreement includes an upfront payment of US$20 million, a further US$5 million in the fourth quarter of 2025, and potential near-term milestone payments of up to US$13 million. This update aims to enhance transparency by providing investors with more detailed information on the potential near-term milestone payments. The revised announcement supersedes the earlier version issued on the same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL1dmQ9l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"2575524747","title":"BRIEF-Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus","url":"https://stock-news.laohu8.com/highlight/detail?id=2575524747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575524747?lang=en_us&edition=fundamental","pubTime":"2025-10-16 22:15","pubTimestamp":1760624105,"startTime":"0","endTime":"0","summary":"BRIEF-Nanjing Leads Biolabs Signs Exclusive Global License Agreement With DianthusOct 16  - Nanjing Leads Biolabs Co Ltd 9887.HK:EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH DIANTHUS FOR LBL-047WILL RECEIVE UPFRONT AND POTENTIAL NEAR-TERM MILESTONE PAYMENTS UP TO $38 MILLION, UP TO $1 BILLION IN POTENTIAL CLINICAL DEVELOPMENTFurther company coverage: 9887.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX2MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161"],"gpt_icon":0},{"id":"1169572079","title":"LEADS BIOLABS-B (09887) Signs Global Exclusive License Agreement with DIANTHUS for LBL-047","url":"https://stock-news.laohu8.com/highlight/detail?id=1169572079","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169572079?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:58","pubTimestamp":1760619517,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced on October 16, 2025, that it has entered into a global exclusive licensing agreement with Dianthus Therapeutics, Inc. (Dianthus, Nasdaq: DNTH). This partnership will...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887"],"gpt_icon":0},{"id":"2575749948","title":"Nanjing Leads Biolabs - Exclusive Global License Agreement With Dianthus for Lbl-047","url":"https://stock-news.laohu8.com/highlight/detail?id=2575749948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575749948?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:49","pubTimestamp":1760618947,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX2MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}]}}